Last Week’s Hot Topic on Cystic Fibrosis

news_9-21

Last week’s hot topic on Cystic Fibrosis titled Phase 3 Trial of Inhaled Antibiotic to Treat CF-related Lung Infections Supported by $20M in New Financing was written by Daniela Semedo.

The article is focused on Savara Pharmaceuticals recently announcing that it has closed a $20 million Series C financing round, which will be used to advance a pivotal Phase 3 clinical trial of AeroVanc (vancomycin hydrochloride inhalation powder), the first dry powder inhaled antibiotic being developed for the treatment of methicillin-resistant staphylococcus aureus (MRSA) lung infection in cystic fibrosis (CF) patients.

Read more articles about cystic fibrosis here: http://bit.ly/1jNDqsz

Leave a Comment

Your email address will not be published. Required fields are marked *